The U.S. Food and Drug Administration has assigned priority review designation to Axsome’s AXS-05 for the treatment of agitation associated with Alzheimer’s disease. This follows a 2020 Breakthrough Therapy designation and shortens the review timeline, with an action date set for April 30, 2026. Management highlights that up to 76% of Alzheimer’s patients experience agitation, underscoring a significant unmet need. Investors view the priority review as a potential catalyst, given the accelerated path to market and the high prevalence of the condition.

Auvelity, Axsome’s oral treatment for major depressive disorder, continues to dominate the company’s top line. In the third quarter, sales of Auvelity grew 69% year-over-year and accounted for 80% of total revenue. This surge reflects both expanded prescribing and patient adoption. Axsome’s gross margin stands above 90%, bolstered by high product uptake and favorable pricing dynamics in the depression market.

Axsome received positive feedback from FDA meeting minutes on its regulatory data package for AXS-12, an investigational treatment for narcolepsy. The company expects to submit a New Drug Application next month, marking a second near-term opportunity for pipeline expansion. Analysts note that successful approval and launch of AXS-12 could diversify Axsome’s revenue streams beyond Auvelity and further leverage its commercial infrastructure.

Axsome shares experienced a significant jump on higher-than-average volume, driven in part by short covering and renewed buy-side interest. Short interest represented nearly 7% of the float, suggesting squeezed positions contributed to the rally. Several firms have reiterated buy ratings, and at least one increased its target by double digits. The combination of regulatory milestones and robust sales growth has strengthened investor conviction in Axsome’s near- and mid-term outlook.